BackJasper Therapeutics- Warrants (24/09/2026) Overview
Jasper Therapeutics Inc - Warrants (24/09/2026)

Jasper Therapeutics- Warrants (24/09/2026) Return on Equity

Valuation check: JSPRW's ROE is -818.74%, below the sector sector average of -4.47%.

Get informed when a big investor buys or sells

+ Follow

ROE

-818.74%

Return on Equity

-818.74%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Jasper Therapeutics- Warrants (24/09/2026) (JSPRW) FAQ

Jasper Therapeutics- Warrants (24/09/2026) posts a ROE of -818.74%. That is below the sector sector average of -4.47%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For its sector stocks, a ROE near -4.47% is typical. Jasper Therapeutics- Warrants (24/09/2026)'s -818.74% is lower that level. That is roughly 18223.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Jasper Therapeutics- Warrants (24/09/2026)'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -818.74%; use YoY and peer views to separate noise from signal.

Context for JSPRW's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -4.47%), and (3) consistency with growth and profitability. This page covers the first two; Jasper Therapeutics- Warrants (24/09/2026)'s other metric pages and overview cover the third.